<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340326</url>
  </required_header>
  <id_info>
    <org_study_id>Donga 419</org_study_id>
    <nct_id>NCT01340326</nct_id>
  </id_info>
  <brief_title>The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling</brief_title>
  <acronym>VALID</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin-converting enzyme inhibitors and angiotensin-receptor blocker valsartan&#xD;
      ameliorate ventricular remodeling after myocardial infarction (MI). Although the amount of&#xD;
      those drugs used in previous clinical trials, therefore recommended in practical guidelines&#xD;
      is maximum clinical dose, it has not been clearly demonstrated whether the recommended dose&#xD;
      is more efficacious compared to lower dose commonly used in clinical practice. In addition,&#xD;
      the impact of genetic polymorphism in neurohormonal system on the pharmacological effect has&#xD;
      not been explored in the setting of post-MI remodeling.&#xD;
&#xD;
      Therefore, the investigators evaluate whether submaximal dose, which are lower than those in&#xD;
      major pivotal trials but typically used in clinical practice, can offer similar benefit in&#xD;
      post-MI ventricular remodeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1116 patients with left ventricular (LV) dysfunction following the first episode&#xD;
      of acute ST-elevation MI are to be enrolled and randomized to maximal tolerable dose (up to&#xD;
      320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio.&#xD;
      Echocardiographic analysis for quantifying post-MI ventricular remodeling and genotyping of&#xD;
      blood samples are conducted in central core laboratory. Clinical assessment and laboratory&#xD;
      test are performed at fixed times, and genetic polymorphisms of the patients are tested at&#xD;
      the time of admission.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the left ventricular volume index from baseline to follow-up</measure>
    <time_frame>at 24hrs, 1month, and 12months after myocardial infarction</time_frame>
    <description>We measured a left ventriular volume index by echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular volume index</measure>
    <time_frame>at 12months after myocardial infarction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical events</measure>
    <time_frame>during 12 months follow up</time_frame>
    <description>Clinical events were defined as all cause death and hospitalization due to cardiovascular problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical events</measure>
    <time_frame>at 12 months after myocardial infarction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Valsartan,high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose group (valsartan up to 320 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan, usual dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>usual dose group (valsartan 80 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose of valsartan</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Valsartan,high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual dose of valsartan</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Valsartan, usual dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both gender&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  First episode of acute ST-elevation MI&#xD;
&#xD;
          -  An echocardiographic left ventricular ejection fraction less than 50 %&#xD;
&#xD;
          -  Patients who provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for use of angiotensin receptor blockers (ARBs)(hypersensitivity,&#xD;
             pregnancy, bilateral renal artery stenosis)&#xD;
&#xD;
          -  Urgent need for revascularization procedure&#xD;
&#xD;
          -  Severe heart failure (need for intravenous inotropic support)&#xD;
&#xD;
          -  Persistent (&gt; 1 hour) severe hypotension (systolic blood pressure &lt; 90 mmHg)&#xD;
&#xD;
          -  Refractory or potentially lethal arrhythmias&#xD;
&#xD;
          -  Hemodynamically significant right ventricular infarction&#xD;
&#xD;
          -  Primary valvular diseases&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Idiopathic hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Concomitant inflammatory cardiopathy&#xD;
&#xD;
          -  Significant hepatic dysfunction&#xD;
&#xD;
          -  Significant renal dysfunction&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 10 mg/mL)&#xD;
&#xD;
          -  Psychiatric disorders, alcohol or durg abuse&#xD;
&#xD;
          -  Any concomitant disease that might interfere with drug evaluation (especially if life&#xD;
             expectancy is less than 1 year)&#xD;
&#xD;
          -  Participation in any other pharmacological study within 2 months&#xD;
&#xD;
          -  Refusal or inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine,Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Kyungil Park</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Post myocardial infarction ventricular remodeling</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

